Liver Failure (Hepatic Insufficiency) - Pipeline Review, H1 2018

  • ID: 4576096
  • Report
  • 101 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • AVM Biotechnology LLC
  • Daewoong Co Ltd
  • MallInckrodt Plc
  • Mylan NV
  • PledPharma AB
  • Synlogic Inc
  • MORE
Liver Failure (Hepatic Insufficiency) - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Liver Failure (Hepatic Insufficiency) - Pipeline Review, H1 2018, provides an overview of the Liver Failure (Hepatic Insufficiency) (Gastrointestinal) pipeline landscape.

Liver failure is severe deterioration of liver function. Liver failure occurs when a large portion of the liver is damaged due to any type of liver disorder. Symptoms may include jaundice, tendency to bruise or bleed easily, ascites, impaired brain function (encephalopathy), poor weight gain and growth, fatigue, weakness, nausea and loss of appetite. Since these symptoms are associated with a host of other conditions, it may take some time before the correct diagnosis is made. As liver failure worsens, people may experience disorientation and drowsiness. At this stage, there is a risk of coma and death.

Report Highlights:

This latest pipeline guide Liver Failure (Hepatic Insufficiency) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Liver Failure (Hepatic Insufficiency) (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Liver Failure (Hepatic Insufficiency) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Liver Failure (Hepatic Insufficiency) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 4, 3, 1, 10, 1 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Liver Failure (Hepatic Insufficiency) (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Liver Failure (Hepatic Insufficiency) (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Liver Failure (Hepatic Insufficiency) (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Liver Failure (Hepatic Insufficiency) (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Liver Failure (Hepatic Insufficiency) (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Liver Failure (Hepatic Insufficiency) (Gastrointestinal)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Liver Failure (Hepatic Insufficiency) (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Liver Failure (Hepatic Insufficiency) (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AVM Biotechnology LLC
  • Daewoong Co Ltd
  • MallInckrodt Plc
  • Mylan NV
  • PledPharma AB
  • Synlogic Inc
  • MORE
Introduction

Report Coverage

Liver Failure (Hepatic Insufficiency) - Overview

Liver Failure (Hepatic Insufficiency) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Liver Failure (Hepatic Insufficiency) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Liver Failure (Hepatic Insufficiency) - Companies Involved in Therapeutics Development

AVM Biotechnology LLC

Celgene Corp

Cell2B Advanced Therapeutics SA

Daewoong Co Ltd

Genentech Inc

Immune Pharmaceuticals Inc

MallInckrodt Plc

Martin Pharmaceuticals Inc

Mina Therapeutics Ltd

Mylan NV

Novartis AG

PledPharma AB

Promethera Biosciences SA

Synlogic Inc

Takeda Pharmaceutical Co Ltd

Therapure Biopharma Inc

Unicyte AG

Versantis AG

Vital Therapies Inc

Liver Failure (Hepatic Insufficiency) - Drug Profiles

albumin (human) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cell Therapy for Liver Failure - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cell Therapy for Liver Failure and Alcoholic Hepatitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DWSR-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

emricasan - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

enasidenib mesylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

F-573 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HepaStem - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ImmuneSafe - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ipatasertib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MTL-CEBPA - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ornithine phenylacetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PP-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

resatorvid - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

silibinin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Acute Liver Failure and Non-Alcoholic Steatohepatitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit CYP3A4 for Liver Failure - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit MKK4 for Acute Liver Failure and Chronic Liver Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Diabetes Mellitus, Acute Liver Failure, Osteoarthritis and Neurodegenerative Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Liver Failure - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Type 1 Diabetes, Urea Cycle Disorders and Acute Liver Failure - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SYNB-1020 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

trimetazidine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VS-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XEN-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Liver Failure (Hepatic Insufficiency) - Dormant Projects

Liver Failure (Hepatic Insufficiency) - Discontinued Products

Liver Failure (Hepatic Insufficiency) - Product Development Milestones

Featured News & Press Releases

May 14, 2018: PledPharma has completed the recruitment for the clinical trial with Aladote

Mar 29, 2018: Martin Pharmaceuticals Receives FDA Orphan Drug Designation for LIVANTRA

Mar 28, 2018: PledPharma receives European approval of the composition of matter patent for Aladote

Dec 12, 2017: Principal investigator James Dear presents Aladote as a potential new treatment for late stage liver toxicity after paracetamol overdose at Pharmacology conference

Dec 04, 2017: Vital Therapies Appoints Russell J. Cox as Chief Executive Officer and Board Member Effective January 3, 2018

Oct 04, 2017: Principal investigator of Aladote study James Dear presents calmangafodipir as a potential new treatment for late stage liver toxicity after acetaminophen overdose at liver disease conference

Sep 14, 2017: The Aladote study in patients treated for paracetamol overdose is now open for recruitment for the next dosage group

Sep 06, 2017: Vital Therapies Appoints Former Receptos President and CEO Faheem Hasnain as Chairman of the Board of Directors

Jul 17, 2017: Versantis Announces FDA Grants Orphan Drug Designation to VS-01 for the Treatment of Acute-on-Chronic Liver Failure

Jun 08, 2017: First patient included in PledPharma's clinical trial with Aladote

Oct 24, 2016: Ocera Therapeutics Announces Late-Breaker Abstract Accepted for Presentation at the AASLD Liver Meeting 2016

Sep 21, 2016: Ocera Announces Enrollment Completion From Phase 2a NIH-Sponsored Study of OCR-002 in the Treatment of Patients with Acute Liver Failure

May 17, 2016: COMP Issued a Positive Opinion on Orphan Medicinal Product Designation for VS-01 for The Treatment of Acute Liver Failure

Feb 29, 2016: Versantis Receives Confirmation From The EMA that Its Application for Orphan Drug Designation in Acute Liver Failure Is Valid

Jan 31, 2016: Versantis Initiates the Manufacturing Scale Up of VS-01

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Liver Failure (Hepatic Insufficiency), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Liver Failure (Hepatic Insufficiency) - Pipeline by AVM Biotechnology LLC, H1 2018

Liver Failure (Hepatic Insufficiency) - Pipeline by Celgene Corp, H1 2018

Liver Failure (Hepatic Insufficiency) - Pipeline by Cell2B Advanced Therapeutics SA, H1 2018

Liver Failure (Hepatic Insufficiency) - Pipeline by Daewoong Co Ltd, H1 2018

Liver Failure (Hepatic Insufficiency) - Pipeline by Genentech Inc, H1 2018

Liver Failure (Hepatic Insufficiency) - Pipeline by Immune Pharmaceuticals Inc, H1 2018

Liver Failure (Hepatic Insufficiency) - Pipeline by MallInckrodt Plc, H1 2018

Liver Failure (Hepatic Insufficiency) - Pipeline by Martin Pharmaceuticals Inc, H1 2018

Liver Failure (Hepatic Insufficiency) - Pipeline by Mina Therapeutics Ltd, H1 2018

Liver Failure (Hepatic Insufficiency) - Pipeline by Mylan NV, H1 2018

Liver Failure (Hepatic Insufficiency) - Pipeline by Novartis AG, H1 2018

Liver Failure (Hepatic Insufficiency) - Pipeline by PledPharma AB, H1 2018

Liver Failure (Hepatic Insufficiency) - Pipeline by Promethera Biosciences SA, H1 2018

Liver Failure (Hepatic Insufficiency) - Pipeline by Synlogic Inc, H1 2018

Liver Failure (Hepatic Insufficiency) - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2018

Liver Failure (Hepatic Insufficiency) - Pipeline by Therapure Biopharma Inc, H1 2018

Liver Failure (Hepatic Insufficiency) - Pipeline by Unicyte AG, H1 2018

Liver Failure (Hepatic Insufficiency) - Pipeline by Versantis AG, H1 2018

Liver Failure (Hepatic Insufficiency) - Pipeline by Vital Therapies Inc, H1 2018

Liver Failure (Hepatic Insufficiency) - Dormant Projects, H1 2018

Liver Failure (Hepatic Insufficiency) - Dormant Projects, H1 2018 (Contd..1), H1 2018

Liver Failure (Hepatic Insufficiency) - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Liver Failure (Hepatic Insufficiency), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • AVM Biotechnology LLC
  • Celgene Corp
  • Cell2B Advanced Therapeutics SA
  • Daewoong Co Ltd
  • Genentech Inc
  • Immune Pharmaceuticals Inc
  • MallInckrodt Plc
  • Martin Pharmaceuticals Inc
  • Mina Therapeutics Ltd
  • Mylan NV
  • Novartis AG
  • PledPharma AB
  • Promethera Biosciences SA
  • Synlogic Inc
  • Takeda Pharmaceutical Co Ltd
  • Therapure Biopharma Inc
  • Unicyte AG
  • Versantis AG
  • Vital Therapies Inc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll